GeneBioTech Co Ltd
KOSDAQ:086060
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
GeneBioTech Co Ltd
Income from Continuing Operations
GeneBioTech Co Ltd
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
G
|
GeneBioTech Co Ltd
KOSDAQ:086060
|
Income from Continuing Operations
₩3.7B
|
CAGR 3-Years
76%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
21%
|
|
|
Celltrion Inc
KRX:068270
|
Income from Continuing Operations
₩1T
|
CAGR 3-Years
25%
|
CAGR 5-Years
14%
|
CAGR 10-Years
22%
|
|
|
O
|
OliX Pharmaceuticals Inc
KOSDAQ:226950
|
Income from Continuing Operations
-₩15.7B
|
CAGR 3-Years
18%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Income from Continuing Operations
-₩32.6B
|
CAGR 3-Years
-28%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Income from Continuing Operations
₩145.2B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
61%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Income from Continuing Operations
-₩37.9B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
GeneBioTech Co Ltd
Glance View
Gene Bio Tech Co., Ltd. engages in the manufacture of fermented biomass. The company is headquartered in Gongju, Chungcheongnam-Do. The company went IPO on 2006-04-28. is a company mainly engaged in the production and sale of feed additives and animal drugs. Along with subsidiaries, the Company operates its business through two segments. The Additive segment is involved in the manufacturing and sale of fermented products and bio starches. The Animal Drug segment is involved in the manufacturing and sale of livestock and fish medicine. The main products include vitamins, minerals, antibiotics, nutrients, immune stimulators, digestion and absorption promoters, among others. The firm distributes its products within the domestic market and to overseas markets, including America.
See Also
What is GeneBioTech Co Ltd's Income from Continuing Operations?
Income from Continuing Operations
3.7B
KRW
Based on the financial report for Sep 30, 2025, GeneBioTech Co Ltd's Income from Continuing Operations amounts to 3.7B KRW.
What is GeneBioTech Co Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
21%
Over the last year, the Income from Continuing Operations growth was 44%. The average annual Income from Continuing Operations growth rates for GeneBioTech Co Ltd have been 76% over the past three years , and 21% over the past ten years .
